Sugi Predict

Sugi Predict / Compounds / SCHEMBL3839876

SCHEMBL3839876

SCHEMBL3839876

O=C(O[C@H]1CCOC1)O[C@H]1CCOC1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.38
▸ MAPK8 P45983 1/20 0.35
▸ MAPK9 P45984 1/20 0.35
▸ KAT2B Q92831 1/20 0.34
▸ BAZ2B Q9UIF8 1/20 0.34
▸ ATF4 P18848 1/20 0.34
▸ PDE4D Q08499 6/20 0.33
▸ ACACB O00763 4/20 0.33
▸ PDE4A P27815 3/20 0.33
▸ PDE4B Q07343 3/20 0.33
▸ PDE4C Q08493 3/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ GRM5 P41594 2/20 0.33
▸ GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999275 1.00 CTSL (0.38) CTSLMAPK8MAPK9KAT2BBAZ2B
SCHEMBL25394555 1.00 CTSL (0.38) CTSLMAPK8MAPK9KAT2BBAZ2B
SCHEMBL7055943 0.92 PDE4D (0.38) CTSLMAPK8MAPK9KAT2BBAZ2B
SCHEMBL14065829 0.87 CTSL (0.33) CTSLMAPK8MAPK9
SCHEMBL1023586 0.85 KAT2B (0.43) KAT2BBAZ2BPDE4DACACBPDE4A
SCHEMBL2286907 0.84 — —
SCHEMBL2011670 0.84 — —
SCHEMBL1691304 0.84 — —
SCHEMBL2447355 0.84 — —
Hydrochloric Acid SCHEMBL3966985 0.83 KAT2B (0.42) KAT2BBAZ2BACACBEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder OSAKA CITY UNIVERSITY (JP) 2023-12-19 — — US disclosed
US-20230382940-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2023-11-30 — — US disclosed
WO-2023168254-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2023-09-07 — — WO disclosed
US-20190314320-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER OSAKA CITY UNIVERSITY (JP) 2019-10-17 — — US disclosed
EP-3466421-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER Osaka City University (JP) 2019-04-10 — — EP disclosed
EP-2647386-B1 LISSENCEPHALY THERAPEUTIC AGENT UNIV OSAKA CITY (JP) 2018-09-05 — — EP disclosed
US-9539298-B2 Lissencephaly therapeutic agent OSAKA CITY UNIVERSITY (JP) 2017-01-10 — — US disclosed
US-20160250276-A1 LISSENCEPHALY THERAPEUTIC AGENT OSAKA CITY UNIVERSITY (JP) 2016-09-01 — — US disclosed
US-9371359-B2 Lissencephaly therapeutic agent OSAKA CITY UNIVERSITY (JP) 2016-06-21 — — US disclosed
EP-2647386-A1 LISSENCEPHALY THERAPEUTIC AGENT Osaka City University (JP) 2013-10-09 — — EP disclosed
US-20040127488-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2004-07-01 — — US disclosed
US-6617350-B2 Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity VERTEX PHARMACEUTICALS INCORPORATED 2003-09-09 — — US disclosed
US-6573388-B1 Synthetic intermediates for the synthesis of HIV protease inhibitors and oligopeptide mimetics SAMCHULLY PHARM. CO., LTD. (KR) 2003-06-03 — — US disclosed
US-20020198388-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-12-26 — — US disclosed
EP-1159278-A2 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-12-05 — — EP disclosed
US-6319946-B1 BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED 2001-11-20 — — US disclosed
WO-2001012599-A1 NEW ETHYLAZIRIDINE DERIVATIVES AND THEIR PREPARATION METHODS SAMCHULLY PHARM CO., LTD. (KR) 2001-02-22 — — WO disclosed
WO-2000047551-A2 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-08-17 — — WO disclosed
EP-1001969-A1 PEPTIDOMIMETIC DERIVATIVES SUICIDAL INHIBITORS OF THE HIV PROLIFERATION ZAMBON GROUP S.p.A. (IT) 2000-05-24 — — EP disclosed
WO-1999001470-A2 PEPTIDOMIMETIC DERIVATIVES SUICIDAL INHIBITORS OF THE HIV PROLIFERATION ZAMBON GROUP S.P.A. (IT) 1999-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382940-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME EIF2AK2, MAVS, ZC3HAV1 CTSL 164/4885MAPK8 4230/4885MAPK9 4507/4885
US-20190314320-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER PMP22, PRPH, NGF CTSL 4677/4885MAPK8 4297/4885MAPK9 3716/4885
US-20040127488-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 CTSL 74/4885MAPK8 3781/4885MAPK9 3869/4885
US-20020198388-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 CTSL 74/4885MAPK8 3781/4885MAPK9 3869/4885
US-20160250276-A1 LISSENCEPHALY THERAPEUTIC AGENT ASPH, DCX, P4HA1 CTSL 3699/4885MAPK8 3215/4885MAPK9 3396/4885
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder PMP22, PRPH, NGF CTSL 4677/4885MAPK8 4297/4885MAPK9 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.